Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Heidelberg University · University Hospital Heidelberg · +2 more institutions
Abstract
PURPOSE: Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS: This noninferiority, phase III, randomized study compared the overall survival between treatment arms using a fixed margin method (hazard ratio [HR]
Citation impact
- FWCI
- 187.38
- Percentile
- 100%
- References
- 34
Authors
20- GVGiorgio V. ScagliottiCorresponding
Heidelberg University, University Hospital Heidelberg, Frauenklinik Heidelberg
- PPPurvish Parikh
Heidelberg University, University Hospital Heidelberg, Frauenklinik Heidelberg
- JVJoachim von Pawel
Heidelberg University, University Hospital Heidelberg, Frauenklinik Heidelberg
- BBBonne Biesma
Heidelberg University, University Hospital Heidelberg, Frauenklinik Heidelberg
- JVJohan Vansteenkiste
Heidelberg University, University Hospital Heidelberg, Frauenklinik Heidelberg
Topics & keywords
- Pemetrexed
- Gemcitabine
- Medicine
- Cisplatin
- Internal medicine
- Neutropenia
- Lung cancer
- Febrile neutropenia
- Good health and well-being